Actively Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Led by Immuneering Corporation · Updated on 2026-05-06
510
Participants Needed
6
Research Sites
143 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
CONDITIONS
Official Title
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must be 18 years of age or older
- Must have confirmed diagnosis of metastatic pancreatic adenocarcinoma at least 12 weeks prior to screening according to AJCC staging
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- First-line pancreatic ductal adenocarcinoma participants must have received no previous systemic anti-cancer therapy
- Must have measurable disease with at least one target lesion per RECIST v1.1 criteria
- Must have adequate organ function, hepatic function, coagulation studies, and clinical laboratory values as determined by the protocol
You will not qualify if you...
- Inability to swallow oral medications
- Diagnosis of squamous, adenosquamous, neuroendocrine (carcinoid, islet cell), or acinar pancreatic carcinoma
- Presence of only locally advanced disease
- Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
City of Hope
Phoenix, Arizona, United States, 85338
Actively Recruiting
2
City of Hope
Duarte, California, United States, 91010
Actively Recruiting
3
City of Hope
Chicago, Illinois, United States, 60099
Actively Recruiting
4
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
5
Taylor Cancer Research Center
Maumee, Ohio, United States, 43537
Actively Recruiting
6
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Actively Recruiting
Research Team
I
Immuneering Study Team
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here